Treatment with zenocutuzumab has been shown to decrease phosphorylation of HER2, HER3, EGFR, and HER4 and reduce NRG1 fusion-dependent oncogenic signaling, thereby suppressing tumor growth in preclinical models [56]. The gene discussed is ERBB2; the disease is neoplasm.